Literature DB >> 23319087

Hospital-onset seizures: an inpatient study.

Madeline C Fields1, Daniel L Labovitz, Jacqueline A French.   

Abstract

OBJECTIVES: To describe demographic and clinical characteristics of patients with hospital-onset seizure (HOS) and to explore current practices in their management.
DESIGN: Retrospective medical record review.
SETTING: Academic, tertiary care, private (New York University Langone Medical Center) and municipal (Bellevue Hospital Center) medical centers. PATIENTS: Patients aged at least 18 years with HOS from January 1 through December 31, 2007. Patients admitted for evaluation of seizures or epilepsy were excluded. MAIN OUTCOME MEASURES: Hospital-onset seizure patterns, medication use, and outcomes.
RESULTS: We identified 218 patients with HOS; 139 (64%) had no history of seizure. Hospital-onset seizures were recurrent in 134 patients (61%) during the inpatient stay and were more likely to recur in those with new-onset seizure vs those with a history of seizure (43% vs 32%, P = .09). The most commonly described HOS in patients with a history of seizure and patients with new-onset seizure was a generalized tonic-clonic seizure (72 [33%]). Metabolic derangements were the most common identifiable cause of HOS (43 of 218 [20%]) and new-onset seizures (35 of 139 [25%]) and were more likely to recur. Phenytoin was the most common antiepileptic drug prescribed de novo (61%). Death during hospitalization or discharge to hospice was more common in patients with new-onset seizures compared with those with a history of seizure (19% vs 5%, P = .004). Among surviving patients discharged with a prescription of antiepileptic drugs, phenytoin and levetiracetam were prescribed most often.
CONCLUSIONS: Hospital-onset seizures commonly occur as new-onset seizures, are typically recurrent, and are associated with a high mortality. Older antiepileptic drugs are often prescribed at seizure presentation and at discharge.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319087     DOI: 10.1001/2013.jamaneurol.337

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  7 in total

Review 1.  Acute Symptomatic Seizures and Provoked Seizures: to Treat or Not to Treat?

Authors:  Nisali Gunawardane; Madeline Fields
Journal:  Curr Treat Options Neurol       Date:  2018-08-23       Impact factor: 3.598

2.  Antiepileptic Drug Management in Hospitalized Epilepsy Patients With Nil Per Os Diets: A Retrospective Review.

Authors:  Anna M Bank; Jong Woo Lee; Alexa N Ehlert; Aaron L Berkowitz
Journal:  Neurohospitalist       Date:  2018-09-27

3.  Presentation and management of community-onset vs hospital-onset first seizures.

Authors:  Emma Foster; Sarah Holper; Zhibin Chen; Patrick Kwan
Journal:  Neurol Clin Pract       Date:  2018-10

Review 4.  Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Eri Tsukagoshi; Yoichi Tanaka; Yoshiro Saito
Journal:  Front Med (Lausanne)       Date:  2021-03-24

5.  Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals.

Authors:  Silky Beaty; Ning A Rosenthal; Julie Gayle; Prashant Dongre; Kristen Ricchetti-Masterson
Journal:  Front Neurol       Date:  2021-11-29       Impact factor: 4.003

Review 6.  Intravenous Brivaracetam in the Management of Acute Seizures in the Hospital Setting: A Scoping Review.

Authors:  Kiwon Lee; Pavel Klein; Prashant Dongre; Eun Jung Choi; Denise H Rhoney
Journal:  J Intensive Care Med       Date:  2022-03-21       Impact factor: 2.889

7.  Epidemiology and injectable antiseizure medication treatment patterns of seizure patients treated in United States hospitals.

Authors:  Silky Beaty; Ning Rosenthal; Julie Gayle; Prashant Dongre; Kristen Ricchetti-Masterson; Denise H Rhoney
Journal:  Front Neurol       Date:  2022-09-12       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.